DDInter1305 DDInter280
Nitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles). Nitroprusside is often administered intravenously to patients who are experiencing a hypertensive emergency.
Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus , [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes . Cardiovascular disease is the most common cause of death in these patients .
Nitroprusside {u} (Compound) binds {v} (Gene) GUCY1A2
GUCY1A2 {u} (Gene) is bound by {v} (Compound) Nitroglycerin
Nitroglycerin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canagliflozin
Nitroprusside {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Dapagliflozin
Dapagliflozin {u} (Compound) resembles {v} (Compound) Canagliflozin
Nitroprusside {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canagliflozin
Nitroprusside (Compound) binds GUCY1A2 (Gene) and GUCY1A2 (Gene) is bound by Nitroglycerin (Compound) and Nitroglycerin may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Nitroprusside (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Dapagliflozin (Compound) and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Nitroprusside (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin